Hypoxia inducible factor stabilization as a novel strategy to treat anemia

Current Medicinal Chemistry

Volumn 20, Issue 21, 2013, Pages 2697-2711

  Zhao, S ^a   Wu, J ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Anemia; FIH inhibitors; HIF PH pathway; Iron chelators; Natural products; PHD2 inhibitors; Von HippelLindau protein.

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; 1,3 DIKETONE; 2 OXOGLUTARIC ACID; DEFERIPRONE; DEFEROXAMINE; ERYTHROPOIETIN; FLAVONOID; GALLIC ACID; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; IRON CHELATING AGENT; JNJ 42041935; SALIDROSIDE; STABILIZING AGENT; THUJAPLICIN; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CELL HYPOXIA; CELL SURVIVAL; ENZYME ACTIVITY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANEMIA; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; HUMANS;

EID: 84880269329     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320210006     Document Type: Article

References (97)

1. Loor, G.; Schumacker, P.T. Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ., 2008, 15(4), 686-690.
2. Semenza, G.L. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol., 2000, 88(4), 1474-1480.
3. Muchnik, E.; Kaplan, J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin. Invest. Drugs, 2011, 20(5), 645-656.
4. Beuck, S.; Schaenzer, W.; Thevis, M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test. Anal., 2012, 4(11), 830-845.
5. Bakris, G.L.; Yu, K.-H.P.; Leong, R.; Shi, W.; Lee, T.; Saikali, K.; Henry, E.; Neff, T.B. Effects of a Novel Anemia Treatment, FG-4592, an Oral Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) on Blood Pressure and Cholesterol in Patients with Chronic Kidney Disease. J. Clin. Hypertens., 2012, 14(7), 489.
6. Besarab, A.; Belo, D.; Diamond, S.; Martin, E.; Sun, C.; Lee, T.; Saikali, K.; Franco, M.; Leong, R.; Neff, T.; Yu, P. Evaluation of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor FG-4592 for Hemoglobin Correction and Maintenance in Nondialysis Chronic Kidney Disease Patients for 16 and 24 Weeks. Nephrol. Dial. Transpl., 2012, 27(suppl 2), ii133-ii145.
7. Provenzano, R.; Goodkin, D.; Klaus, S.; Linde, P.; Kazazi, F.; Lee, T.; Neff, T.; Yu, P. Evaluation of FG-4592, A Novel Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, to Treat Anemia in Hemodialysis Patients. Am. J. Kidney Dis., 2011, 57(4), B80.
8. Klaus, S.; Langsetmo, I.; Neff, T.; Lin, A.; Liu, D. Beneficial Pharmacodynamic Effects Resulting from 'Complete Erythropoiesis' Induced by Novel HIF Prolyl Hydroxylase Inhibitors FG-2216 and FG-4592 J. Am. Soc. Nephrol., 2008, 19, 524A.
9. McLean, E.; Cogswell, M.; Egli, I.; Wojdyla, D.; de, B.B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr, 2009, 12(4), 444-454.
10. Melnikova, I. Anaemia therapies. Nat. Rev. Drug Discovery, 2006, 5(8), 627-628.
11. Balarajan, Y.; Ramakrishnan, U.; Ozaltin, E.; Shankar, A.H.; Subramanian, S.V. Anaemia in low-income and middle-income countries. Lancet, 2011, 378(9809), 2123-2135.
12. Tolentino, K.; Friedman, J.F. An update on anemia in less developed countries. Am. J. Trop. Med. Hyg., 2007, 77(1), 44-51.
13. Benoist, B.d.; McLean, E.; Egli, I.; Cogswell, M. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. World Health Organization: Switzerland, 2008.
14. In: Quick look nursing: Pathophysiology; Madara, B.; Pomarico-Denino, V., Ed.; Jones and Bartlett Publishers: Sudbury, 2008, 81-104.
15. In: Pharmacology; Finkel, R.; Clark, M.A.; Cubeddu, L.X., Ed.; Lippincott Williams & Wilkins: Philadelphia, 2009; pp. 229-248.
16. Ludwig, H.; Oesterborg, A. In: Current Clinical Oncology: Biology and Management of Multiple Myeloma; Berenson, J.R., Editor; Humana Press Inc.: Totowa, 2004; pp. 303-318.
17. Melosky, B.L. Erythropoiesis-stimulating agents: Benefits and risks in supportive care of cancer. Curr. Oncol., 2008, 15, S10-S15.
18. Reichardt, B. Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. J. Clin. Pharm. Ther., 2006, 31, 503-512.
19. Drueke, T.B.; Locatelli, F.; Clyne, N.; Eckardt, K.-U.; Macdougall, L.C.; Tsakiris, D.; Burger, H.-U.; Scherhag, A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med., 2006, 355, 2071-2084.
20. Singh, A.K.; Szczech, L.; Tang, K.L.; Barnhart, H.; Sapp, S.; Wolfson, M.; Reddan, D. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med., 2006, 355, 2085-2098.
21. Pfeiffer, M.A.; Burdmann, E.A.; Chen, C.-Y.; Cooper, M.E.; De, Z.D.; Eckardt, K.-U.; Feyzi, J.M.; Ivanovich, P.; Kewalramani, R.; Levey, A.S.; Lewis, E.F.; McGill, J.B.; McMurray, J.J.V.; Parfey, P.; Parving, H.-H.; Remuzzi, G.; Singh, A.K.; Solomon, S.D.; Toto, R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med., 2009, 361, 2019-2032.
22. Kanbay, M.; Perazella, M.A.; Kasapoglu, B.; Koroglu, M.; Covic, A. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: Review of causes and management. Blood Purif, 2010, 29, 1-12.
23. Johnson, D.W.; Pollock, C.A.; MacDougall, I.C. Erythropoiesisstimulating agent hyporesponsiveness. Nephrology, 2007, 12, 321-330.
24. Macdougall, I.C. New anemia therapies: Translating novel strategies from bench to bedside. Am. J. Kidney Dis., 2012, 59(3), 444-451.
25. Rabinowitz, M.H.; Barrett, T.D.; Rosen, M.D.; Venkatesan, H. Inhibitors of HIF prolyl hydroxylases. Annu. Rep. Med. Chem., 2010, 45, 123-139.
26. Beall, C.M. High-altitude adaptations. Lancet, 2003, 362 Suppl, s14-s15.
27. Semenza, G.L.; Wang, G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol., 1992, 12(12), 5447-5454.
28. Wang, G.L.; Semenza, G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem., 1995, 270(3), 1230-1237.
29. Wang, G.L.; Jiang, B.-H.; Rue, E.A.; Semenza, G.L. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 5510-5514.
30. Loboda, A.; Jozkowicz, A.; Dulak, J. HIF-1 versus HIF-2-Is one more important than the other? Vasc. Pharmacol., 2012, 56(5-6), 245-251.
31. Rosen, M.D.; Venkatesan, H.; Peltier, H.M.; Bembenek, S.D.; Kanelakis, K.C.; Zhao, L.X.; Leonard, B.E.; Hocutt, F.M.; Wu, X.; Palomino, H.L.; Brondstetter, T.I.; Haugh, P.V.; Cagnon, L.; Yan, W.; Liotta, L.A.; Young, A.; Mirzadegan, T.; Shankley, N.P.; Barrett, T.D.; Rabinowitz, M.H. Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues. ACS Med. Chem. Lett., 2010, 1(9), 526-529.
32. Jaakkola, P.; Mole, D.R.; Tian, Y.-M.; Wilson, M.I.; Gielbert, J.; Gaskell, S.J.; von, K.A.; Hebestreit, H.F.; Mukherji, M.; Schofield, C.J.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J. Targeting of HIF-k to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (Washington, DC, U. S.), 2001, 292(5516), 468-472.
33. Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J.M.; Lane, W.S.; Kaelin, W.G., Jr. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science (Washington, DC, U. S.), 2001, 292(5516), 464-468.
34. Smirnova, N.A.; Hushpulian, D.M.; Speer, R.E.; Gaisina, I.N.; Ratan, R.R.; Gazaryan, I.G. Catalytic mechanism and substrate specificity of HIF prolyl hydroxylases. Biochemistry (Moscow), 2012, 77(10), 1108-1119.
35. Hirota, S.A.; Beck, P.L.; MacDonald, J.A. Targeting hypoxiainducible factor-1 (HIF-1) signaling in therapeutics: Implications for the treatment of inflammatory bowel disease. Recent Pat. Inflamm. Allergy Drug Discov., 2009, 3(1), 1-16.
36. Ong, S.-G.; Hausenloy, D.J. Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacol. Ther., 2012, 136(1), 69-81.
37. Li, Y.; Ye, D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr. Cancer Drug Targets, 2010, 10(7), 782-796.
38. Zhang, Z.; Yan, J.; Chang, Y.; Yan, S.S.D.; Shi, H. Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr. Med. Chem., 2011, 18(28), 4335-4343.
39. Hirota, K.; Semenza, G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem. Biophys. Res. Commun., 2005, 338(1), 610-616.
40. Zheng, K.Y.-Z.; Zhang, Z.-X.; Guo, A.J.-Y.; Bi, C.W.-C.; Zhu, K.Y.; Xu, S.L.; Zhan, J.Y.-X.; Lau, D.T.-W.; Dong, T.T.-X.; Choi, R.C.-Y.; Tsim, K.W.-K. Salidroside stimulates the accumulation of HIF-1β protein resulted in the induction of EPO expression: A signaling via blocking the degradation pathway in kidney and liver cells. Eur. J. Pharmacol., 2012, 679(1-3), 34-39.
41. Lando, D.; Peet, D.J.; Whelan, D.A.; Gorman, J.J.; Whitelaw, M.L. Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science (Washington, DC, U. S.), 2002, 295(5556), 858-861.
42. Greer, S.N.; Metcalf, J.L.; Wang, Y.; Ohh, M. The updated biology of hypoxia-inducible factor. EMBO J., 2012, 31(11), 2448-2460.
43. Yang, M.; Ge, W.; Chowdhury, R.; Claridge, T.D.W.; Kramer, H.B.; Schmierer, B.; McDonough, M.A.; Gong, L.; Kessler, B.M.; Ratcliffe, P.J.; Coleman, M.L.; Schofield, C.J. Asparagine and Aspartate Hydroxylation of the Cytoskeletal Ankyrin Family Is Catalyzed by Factor-inhibiting Hypoxia-inducible Factor. J. Biol. Chem., 2011, 286(9), 7648-7660.
44. Dayan, F.; Monticelli, M.; Pouyssegur, J.; Pecou, E. Gene regulation in response to graded hypoxia: The non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathway. J. Theor. Biol., 2009, 259(2), 304-316.
45. Nagle, D.G.; Zhou, Y.-D. Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1). Curr. Pharm. Des., 2006, 12(21), 2673-2688.
46. Wanner, R.M.; Spielmann, P.; Stroka, D.M.; Camenisch, G.; Camenisch, I.; Scheid, A.; Houck, D.R.; Bauer, C.; Gassmann, M.; Wenger, R.H. Epolones induce erythropoietin expression via hypoxia-inducible factor-1β activation. Blood, 2000, 96(4), 1558-1565.
47. Hattori, H.; Okuda, K.; Murase, T.; Shigetsura, Y.; Narise, K.; Semenza, G.L.; Nagasawa, H. Isolation, identification, and biological evaluation of HIF-1-modulating compounds from Brazilian green propolis. Bioorg. Med. Chem., 2011, 19(18), 5392-5401.
48. Jeon, H.; Kim, H.; Choi, D.; Kim, D.; Park, S.-Y.; Kim, Y.-J.; Kim, Y.M.; Jung, Y. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: A structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol. Pharmacol., 2007, 71(6), 1676-1684.
49. Hasebe, Y.; Egawa, K.; Yamazaki, Y.; Kunimoto, S.; Hirai, Y.; Ida, Y.; Nose, K. Specific inhibition of hypoxia-inducible factor (HIF)-1β activation and of vascular endothelial growth factor (VEGF) production by flavonoids. Biol. Pharm. Bull., 2003, 26(10), 1379-1383.
50. Rafehi, H.; Ververis, K.; Balcerczyk, A.; Ziemann, M.; Ooi, J.; Hu, S.; Kwa, F.A.A.; Loveridge, S.J.; Georgiadis, G.T.; El-Osta, A.; Karagiannis, T.C. Investigation of the biological properties of Cinnulin PF in the context of diabetes: Mechanistic insights by genome-wide mRNA-Seq analysis. Pathobiol. Aging Age-Relat. Dis., 2012, 2, 11905.
51. Zhou, Y.-D.; Kim, Y.-P.; Li, X.-C.; Baerson, S.R.; Agarwal, A.K.; Hodges, T.W.; Ferreira, D.; Nagle, D.G. Hypoxia-Inducible Factor-1 Activation by (-)-Epicatechin Gallate: Potential Adverse Effects of Cancer Chemoprevention with High-Dose Green Tea Extracts. J. Nat. Prod., 2004, 67(12), 2063-2069.
52. Tsukiyama, F.; Nakai, Y.; Yoshida, M.; Tokuhara, T.; Hirota, K.; Sakai, A.; Hayashi, H.; Katsumata, T. Gallate, the component of HIF-inducing catechins, inhibits HIF prolyl hydroxylase. Biochem. Biophys. Res. Commun., 2006, 351(1), 234-239.
53. Mecinovic, J.; Chowdhury, R.; Flashman, E.; Schofield, C.J. Use of mass spectrometry to probe the nucleophilicity of cysteinyl residues of prolyl hydroxylase domain 2. Anal. Biochem., 2009, 393(2), 215-221.
54. Chowdhury, R.; McDonough, M.A.; Mecinovic, J.; Loenarz, C.; Flashman, E.; Hewitson, K.S.; Domene, C.; Schofield, C.J. Structural Basis for Binding of Hypoxia-Inducible Factor to the Oxygen-Sensing Prolyl Hydroxylases. Structure (Cambridge, MA, U. S.), 2009, 17(7), 981-989.
55. Nakano, H.; Ikenaga, S.; Aizu, T.; Kaneko, T.; Matsuzaki, Y.; Tsuchida, S.; Hanada, K.; Arima, Y. Human metallothionein gene expression is upregulated by k-thujaplicin: Possible involvement of protein kinase C and reactive oxygen species. Biol. Pharm. Bull., 2006, 29(1), 55-59.
56. Lee, M.J.; Kim, J.W.; Yang, E.G. Hinokitiol activates the hypoxiainducible factor (HIF) pathway through inhibition of HIF hydroxylases. Biochem. Biophys. Res. Commun., 2010, 396(2), 370-375.
57. Chung, L.-C.; Tsui, K.-H.; Feng, T.-H.; Lee, S.-L.; Chang, P.-L.; Juang, H.-H. L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells. Am. J. Physiol. Cell Physiol., 2012, 302(4), C676-685.
58. Lee, J.-J.; Hsu, W.-H.; Yen, T.-L.; Chang, N.-C.; Luo, Y.-J.; Hsiao, G.; Sheu, J.-R. Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats. J. Ethnopharmacol., 2011, 134(3), 824-830.
59. Graziose, R.; Lila, M.A.; Raskin, I. Merging traditional chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr. Drug Discovery Technol., 2010, 7(1), 2-12.
60. Gao, Q.T.; Cheung, J.K.H.; Choi, R.C.Y.; Cheung, A.W.H.; Li, J.; Jiang, Z.Y.; Duan, R.; Zhao, K.J.; Ding, A.W.; Dong, T.T.X.; Tsim, K.W.K. A chinese herbal decoction prepared from Radix Astragali and Radix Angelicae sinensis induces the expression of erythropoietin in cultured Hep3B cells. Planta Med., 2008, 74(4), 392-395.
61. Bi, C.W.C.; Xu, L.; Zhang, W.L.; Zhan, J.Y.X.; Fu, Q.; Zheng, K.Y.Z.; Chen, V.P.; Lau, D.T.W.; Choi, R.C.Y.; Wang, T.J.; Dong, T.T.X.; Tsim, K.W.K. Fo Shou San, an ancient herbal decoction prepared from Angelicae Sinensis Radix and Chuanxiong Rhizoma, induces erythropoietin expression: A signaling mediated by the reduced degradation of hypoxia-inducible factor in cultured liver cells. Planta Med., 2012, 78(2), 122-127.
62. Chang, M.S.; Kim, D.R.; Ko, E.B.; Choi, B.J.; Park, S.Y.; Kang, S.A.; Park, S.K. Treatment with Astragali Radix and Angelicae Radix Enhances Erythropoietin Gene Expression in the Cyclophosphamide-Induced Anemic Rat. J. Med. Food, 2009, 12(3), 637-642.
63. Gaddipati, J.P.; Madhavan, S.; Sidhu, G.S.; Singh, A.K.; Seth, P.; Maheshwari, R.K. Picroliv-A natural product protects cells and regulates the gene expression during hypoxia/reoxygenation. Mol. Cell. Biochem., 1999, 194(1&2), 271-281.
64. Zhang, J.; Liu, A.; Hou, R.; Zhang, J.; Jia, X.; Jiang, W.; Chen, J. Salidroside protects cardiomyocyte against hypoxia-induced death: A HIF-1β-activated and VEGF-mediated pathway. Eur. J. Pharmacol., 2009, 607(1-3), 6-14.
65. Kalinowski, D.S.; Richardson, D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev., 2005, 57(4), 547-583.
66. Liu, Z.D.; Khodr, H.H.; Liu, D.Y.; Lu, S.L.; Hider, R.C. Synthesis, Physicochemical Characterization, and Biological Evaluation of 2-(1'-Hydroxyalkyl)-3-hydroxypyridin-4-ones: Novel Iron Chelators with Enhanced pFe3+ Values. J. Med. Chem., 1999, 42(23), 4814-4823.
67. Dobbin, P.S.; Hider, R.C.; Hall, A.D.; Taylor, P.D.; Sarpong, P.; Porter, J.B.; Xiao, G.; van, d.H.D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: Orally active iron chelators with clinical potential. J. Med. Chem., 1993, 36(17), 2448-2458.
68. Baek, J.H.; Reiter, C.E.N.; Manalo, D.J.; Buehler, P.W.; Hider, R.C.; Alayash, A.I. Induction of hypoxia inducible factor (HIF-1β) in rat kidneys by iron chelation with the hydroxypyridinone, CP94. Biochim. Biophys. Acta, Gene Regul. Mech., 2011, 1809(4-6), 262-268.
69. Flagg, S.C.; Martin, C.B.; Taabazuing, C.Y.; Holmes, B.E.; Knapp, M.J. Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH). J. Inorg. Biochem., 2012, 113, 25-30.
70. Barrett, T.D.; Palomino, H.L.; Brondstetter, T.I.; Kanelakis, K.C.; Wu, X.; Haug, P.V.; Yan, W.; Young, A.; Hua, H.; Hart, J.C.; Tran, D.-T.; Venkatesan, H.; Rosen, M.D.; Peltier, H.M.; Sepassi, K.; Rizzolio, M.C.; Bembenek, S.D.; Mirzadegan, T.; Rabinowitz, M.H.; Shankley, N.P. Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H- pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxiainducible factor prolyl hydroxylase inhibitor. Mol. Pharmacol., 2011, 79(6), 910-920.
71. Berra, E.; Benizri, E.; Ginouves, A.; Volmat, V.; Roux, D.; Pouyssegur, J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1β in normoxia. EMBO Journal, 2003, 22(16), 4082-4090.
72. Warshakoon, N.C.; Wu, S.; Boyer, A.; Kawamoto, R.; Renock, S.; Xu, K.; Pokross, M.; Evdokimov, A.G.; Zhou, S.; Winter, C.; Walter, R.; Mekel, M. Design and synthesis of a series of novel pyrazolylpyridines as HIF 1-α prolyl hydroxylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5687-5690.
73. McDonough, M.A.; Li, V.; Flashman, E.; Chowdhury, R.; Mohr, C.; Lienard, B.M.R.; Zondlo, J.; Oldham, N.J.; Clifton, I.J.; Lewis, J.; McNeill, L.A.; Kurzeja, R.J.M.; Hewitson, K.S.; Yang, E.; Jordan, S.; Syed, R.S.; Schofield, C.J. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 9814-9819.
74. Warshakoon, N.C.; Wu, S.; Boyer, A.; Kawamoto, R.; Sheville, J.; Renock, S.; Xu, K.; Pokross, M.; Zhou, S.; Winter, C.; Walter, R.; Mekel, M.; Evdokimov, A.G. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1β prolyl hydroxylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5517-5522.
75. Tegley, C.M.; Viswanadhan, V.N.; Biswas, K.; Frohn, M.J.; Peterkin, T.A.N.; Chang, C.; Buerli, R.W.; Dao, J.H.; Veith, H.; Rogers, N.; Yoder, S.C.; Biddlecome, G.; Tagari, P.; Allen, J.R.; Hungate, R.W. Discovery of novel hydroxy-thiazoles as HIF-k prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation. Bioorg. Med. Chem. Lett., 2008, 18, 3925-3928.
76. Frohn, M.; Viswanadhan, V.; Pickrell, A.J.; Golden, J.E.; Muller, K.M.; Buerli, R.W.; Biddlecome, G.; Yoder, S.C.; Rogers, N.; Dao, J.H.; Hungate, R.; Allen, J.R. Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1β prolyl hydroxylase-2 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 5023-5026.
77. Teli, M.K.; Rajanikant, G.K. Identification of novel potential HIFprolyl hydroxylase inhibitors by in silico screening. Mol. Diversity, 2012, 16(1), 193-202.
78. Theriault, J.R.; Felts, A.S.; Bates, B.S.; Perez, J.R.; Palmer, M.; Gilbert, S.R.; Dawson, E.S.; Engers, J.L.; Lindsley, C.W.; Emmitte, K.A. Discovery of a new molecular probe ML228: An activator of the hypoxia inducible factor (HIF) pathway. Bioorg. Med. Chem. Lett., 2012, 22(1), 76-81.
79. Denny, W.A. Giving Anemia a Boost with Inhibitors of Prolyl Hydroxylase. J. Med. Chem., 2012, 55(7), 2943-2944.
80. Vachal, P.; Miao, S.; Pierce, J.M.; Guiadeen, D.; Colandrea, V.J.; Wyvratt, M.J.; Salowe, S.P.; Sonatore, L.M.; Milligan, J.A.; Hajdu, R.; Gollapudi, A.; Keohane, C.A.; Lingham, R.B.; Mandala, S.M.; DeMartino, J.A.; Tong, X.; Wolff, M.; Steinhuebel, D.; Kieczykowski, G.R.; Fleitz, F.J.; Chapman, K.; Athanasopoulos, J.; Adam, G.; Akyuz, C.D.; Jena, D.K.; Lusen, J.W.; Meng, J.; Stein, B.D.; Xia, L.; Sherer, E.C.; Hale, J.J. 1,3,8-Triazaspiro[4.5]decane- 2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia. J. Med. Chem., 2012, 55(7), 2945-2959.
81. Bugaut, A.; Jantos, K.; Wietor, J.-L.; Rodriguez, R.; Sanders, J.K.M.; Balasubramanian, S. Exploring the differential recognition of DNA G-quadruplex targets by small molecules using dynamic combinatorial chemistry. Angew. Chem., Int. Ed., 2008, 47, 2677-2680.
82. Demetriades, M.; Leung, I.K.H.; Chowdhury, R.; Chan, M.C.; McDonough, M.A.; Yeoh, K.K.; Tian, Y.-M.; Claridge, T.D.W.; Ratcliffe, P.J.; Woon, E.C.Y.; Schofield, C.J. Dynamic Combinatorial Chemistry Employing Boronic Acids/Boronate Esters Leads to Potent Oxygenase Inhibitors. Angew. Chem., Int. Ed., 2012, 51(27), 6672-6675, S6672/1-S6672/53.
83. Kwon, H.S.; Choi, Y.K.; Kim, J.W.; Park, Y.K.; Yang, E.G.; Ahn, D.-R. Inhibition of a prolyl hydroxylase domain (PHD) by substrate analog peptides. Bioorg. Med. Chem. Lett., 2011, 21(14), 4325-4328.
84. Amelia, S.M. Hydroxypyridinone complexes with aluminum. In vitro/vivo studies and perspectives. Coord. Chem. Rev., 2002, 228(2), 187-203.
85. Zhou, T.; Winkelmann, G.; Dai, Z.-Y.; Hider, R.C. Design of clinically useful macromolecular iron chelators. J. Pharm. Pharmacol., 2011, 63(7), 893-903.
86. Mishra, B.B.; Tiwari, V.K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem., 2011, 46(10), 4769-4807.
87. Murray, J.K.; Balan, C.; Allgeier, A.M.; Kasparian, A.; Viswanadhan, V.; Wilde, C.; Allen, J.R.; Yoder, S.C.; Biddlecome, G.; Hungate, R.W.; Miranda, L.P. Dipeptidyl-Quinolone Derivatives Inhibit Hypoxia Inducible Factor-1β Prolyl Hydroxylases-1,-2, and-3 with Altered Selectivity. J. Comb. Chem., 2010, 12, 676-686.
88. Smirnova, N.A.; Rakhman, I.; Moroz, N.; Basso, M.; Payappilly, J.; Kazakov, S.; Hernandez-Guzman, F.; Gaisina, I.N.; Kozikowski, A.P.; Ratan, R.R.; Gazaryan, I.G. Utilization of an In Vivo Reporter for High Throughput Identification of Branched Small Molecule Regulators of Hypoxic Adaptation. Chem. Biol. (Cambridge, MA, U. S.), 2010, 17(4), 380-391.
89. Thirstrup, K.; Christensen, S.; Moller, H.A.; Ritzen, A.; Bergstroem, A.-L.; Sager, T.N.; Jensen, H.S. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors. Pharmacol. Res., 2011, 64(3), 268-273.
90. Minamishima, Y.A.; Kaelin, W.G., Jr. Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss. Science (Washington, DC, U. S.), 2010, 329(5990), 407.
91. Conejo-Garcia, A.; McDonough, M.A.; Loenarz, C.; McNeill, L.A.; Hewitson, K.S.; Ge, W.; Lienard, B.M.; Schofield, C.J.; Clifton, I.J. Structural basis for binding of cyclic 2-oxoglutarate analogues to factor-inhibiting hypoxia-inducible factor. Bioorg. Med. Chem. Lett., 2010, 20(20), 6125-6128.
92. Cockman, M.E.; Webb, J.D.; Ratcliffe, P.J. FIH-dependent asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Ann. N. Y. Acad. Sci., 2009, 1177(Hypoxia and Consequences), 9-18.
93. McDonough, M.A.; McNeill, L.A.; Tilliet, M.; Papamicaeel, C.A.; Chen, Q.-Y.; Banerji, B.; Hewitson, K.S.; Schofield, C.J. Selective Inhibition of Factor Inhibiting Hypoxia-Inducible Factor. J. Am. Chem. Soc., 2005, 127(21), 7680-7681.
94. Banerji, B.; Conejo-Garcia, A.; McNeill, L.A.; McDonough, M.A.; Buck, M.R.G.; Hewitson, K.S.; Oldham, N.J.; Schofield, C.J. The inhibition of factor inhibiting hypoxia-inducible factor (FIH) by k-oxocarboxylic acids. Chem. Commun. (Cambridge, U. K.), 2005(43), 5438-5440.
95. Moon, H.; Han, S.; Park, H.; Choe, J. Crystal structures of human FIH-1 in complex with quinol family inhibitors. Mol. Cells, 2010, 29(5), 471-474.
96. Ko, S.; Lee, M.K.; Shin, D.; Park, H. Structure-based virtual screening approach to the discovery of novel inhibitors of factorinhibiting HIF-1: Identification of new chelating groups for the active-site ferrous ion. Bioorg. Med. Chem., 2009, 17(22), 7769-7774.
97. Buckley, D.L.; Van, M.I.; Gareiss, P.C.; Tae, H.S.; Michel, J.; Noblin, D.J.; Jorgensen, W.L.; Ciulli, A.; Crews, C.M. Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1β Interaction. J. Am. Chem. Soc., 2012, 134(10), 4465-4468.